Clinical Trial Update: A Safety and Efficacy Study of TALEN and CRISPR/Cas9 in the Treatment of HPV-related Cervical Intraepithelial NeoplasiaⅠ [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating TALEN and CRISPR/Cas9 gene-editing approaches to treat HPV-related cervical intraepithelial neoplasia I, focusing on safety an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Intraepithelial Neoplasia Grade
• Human Papillomavirus Infection

Drugs mentioned

• TALEN and CRISPR/Cas9 gene-editing therapy

Snippet

Sponsor: First Affiliated Hospital, Sun Yat-Sen University | Conditions: Human Papillomavirus-Related Malignant Neoplasm | Phase 1 | Status: UNKNOWN